KingsbergSA, RezaeeRL. Hypoactive sexual desire in women. Menopause, 2013; 20:1284–1300.
2.
LatifEZ, DiamondMP. Arriving at the diagnosis of female sexual dysfunction. Fertil Steril, 2013; 100:898–904.
3.
FaubionSS, ShusterLT, BharuchaAE. Recognition and management of nonrelaxing pelvic floor dysfunction. Mayo Clin Proc, 2012; 87:187–193.
4.
AlthofSE, RosenRC, PerelmanMA, Rubio-AuriolesE. Standard operating procedures for taking a sexual history. J Sex Med, 2013; 10:26–35.
5.
RydingEL, BlomC. Validation of the Swedish version of the Female Sexual Function Index (FSFI) in women with hypoactive sexual desire disorder. J Sex Med, 2015; 12:341–349.
6.
WiegelM, MestonC, RosenR. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther, 2005; 31:1–20.
7.
KrapfJM, SimonJA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas, 2009; 63:213–219.
8.
DavisSR, DavisonSL, DonathS, BellRJ. Circulating androgen levels and self-reported sexual function in women. JAMA, 2005; 294:91–96.
9.
KingsbergSA, WysockiS, MagnusL, KrychmanML. Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med, 2013; 10:1790–1799.
10.
WysockiS, KingsbergS, KrychmanM. Management of vaginal atrophy: Implications from the REVIVE survey. Clin Med Insights Reprod Health, 2014; 8:23–30.
11.
BruyniksN, NappiRE, Castelo-BrancoC, de VilliersTJ, SimonJ. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric, 2016; 19:60–65.
12.
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause, 2013; 20:888–902; quiz 903–4.
13.
EdwardsD, PanayN. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: How important is vaginal lubricant and moisturizer composition?. Climacteric, 2016; 19:151–161.
14.
SalvatoreS, NappiRE, ParmaM, et al.Sexual function after fractional microablative CO(2) laser in women with vulvovaginal atrophy. Climacteric, 2015; 18:219–225.
15.
The North American Menopause Society. Menopause e-Consult. NAMS, 2015; 11:1–4.
16.
MorinM, DumoulinC, BergeronS, et al.Randomized clinical trial of multimodal physiotherapy treatment compared to overnight lidocaine ointment in women with provoked vestibulodynia: Design and methods. Contemp Clin Trials, 2016; 46:52–59.
17.
SchwenkhagenA, StuddJ. Role of testosterone in the treatment of hypoactive sexual desire disorder. Maturitas, 2009; 63:152–159.
18.
WiermanME, ArltW, BassonR, et al.Androgen therapy in women: A reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2014; 99:3489–3510.
19.
ShufeltCL, BraunsteinGD. Safety of testosterone use in women. Maturitas, 2009; 63:63–66.
20.
DavisSR, WorsleyR, MillerKK, ParishSJ, SantoroN. Androgens and female sexual function and dysfunction-findings from the fourth international consultation of sexual medicine. J Sex Med, 2016; 13:168–178.
